AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

February 21, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 21, 2019--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.

“2018 was a critical year for bluebird as the growing body of clinical data from our four lead programs, as well as the investments in our research and development strategy have allowed us to outline a bold vision for the future,” said Nick Leschly, chief bluebird. “We have an unprecedented opportunity in front of us where we anticipate that all four lead programs will have an initial filing or launch by 2022, and we are developing a deep pipeline enabled by our core technologies and our partnerships. Our first approval for LentiGlobin in TDT is anticipated this year and will be a country-by-country progressive European launch. Our strategy is to set ourselves up for long term success – through the development of a seamless delivery network, adoption of value-based payment models and by our continued focus on putting patients first through the entire process. Our goal is to ensure that lives can be lived fully – and I’m confident that our caring and committed team of bluebirds across the U.S. and Europe is up to the task.”

Recent Highlights

TDT

SCD

MULTIPLE MYELOMA

COMPANY

Upcoming Anticipated Milestones

Fourth Quarter and Full Year 2018 Financial Results

About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s financial condition, results of operations, as well as statements regarding the anticipated development for the company’s product candidates, including anticipated regulatory milestones, potential commercial launches, planned clinical studies, as well as the company’s intentions regarding the timing for providing further updates on the development and commercialization of its product candidates. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the preliminary positive efficacy and safety results from our prior and ongoing clinical trials of our product candidates will not continue or be repeated in our ongoing clinical trials, the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates, risks that the current or planned clinical trials of our product candidates will be insufficient to support regulatory submissions or marketing approval in the United States and European Union, the risk that we will encounter challenges in the commercial launch of LentiGlobin in the European Union, including in managing our complex supply chain for the delivery of drug product or in the adoption of value-based payment models or in obtaining sufficient coverage or reimbursement for our products if approved, the risk that our collaborations, including the collaboration with Celgene, will not continue or will not be successful, and the risk that any one or more of our product candidates, will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190221005927/en/

CONTACT: Investors:

bluebird bio

Elizabeth Pingpank, 617-914-8736

epingpank@bluebirdbio.comMedia:

bluebird bio

Jenn Snyder, 617-448-0281

jsnyder@bluebirdbio.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: bluebird bio, Inc.

Copyright Business Wire 2019.

PUB: 02/21/2019 04:05 PM/DISC: 02/21/2019 04:05 PM

http://www.businesswire.com/news/home/20190221005927/en